Clinical Parameters Help Detect Prostate Cancer
Detecting clinically significant disease among PI-RADS category 3 lesions may be improved by incorporating clinical parameters into risk stratification algorithms.
Incorporating clinical parameters into risk stratification algorithms may help clinicians detect clinically significant disease among PI-RADS category 3 lesions, according to a study published in the American Journal of Roentgenology.
Researchers from the University of Colorado in Aurora and Yale University in New Haven, Conn., sought to determine the frequency of clinically significant cancer (CSC) in Prostate Imaging Reporting and Data System (PI-RADS) category 3 (equivocal) lesions prospectively identified on multiparametric prostate MRI. They also wanted to identify risk factors (RFs) for CSC that may aid in decision making.
The imaging results of 977 men who underwent multiparametric prostate MRI and 342 who underwent MRI-ultrasound (US) fusion targeted biopsy were obtained for the trial; 474 lesions were retrospectively reviewed, and 111 were scored as PI-RADS category 3 and visualized using a 3-T MRI scanner. Multiparametric prostate MR images were prospectively interpreted by body subspecialty radiologists trained to use PI-RADS version 2. CSC was defined as a Gleason score of at least 7 on targeted biopsy. A multivariate logistic regression model was constructed to identify the RFs associated with CSC.
The results showed that 81 (73%) of the 111 category 3 lesions were benign; 11 lesions (9.9%) were clinically insignificant with a Gleason score of 6, and 19 lesions (17.1%) were clinically significant. On multivariate analysis, three RFs were identified as significant predictors of CSC:
• Older patient age
• Smaller prostate volume
• Abnormal digital rectal examination (DRE) findings
The risk of CSC for PI-RADS category 3 lesions were:
• 4% with 0
• 16% with 1
• 762% with 2
• 100% with 3
PI-RADS category 3 lesions for which two or more RFs were noted, such as age of 70 years or older; gland size 36 mL or smaller; or abnormal DRE findings, had a CSC detection rate of 67% with a sensitivity of 53%, a specificity of 95%, a positive predictive value of 67%, and a negative predictive value of 91%.
The researchers concluded that by incorporating clinical parameters into risk stratification algorithms, the ability to detect clinically significant disease among PI-RADS category 3 lesions may be improved and it may aid in the decision to perform biopsy.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Is Surveillance Imaging Necessary After Primary Radiation for Head and Neck Cancer?
November 13th 2023For patients who had a complete metabolic response to radiation treatment for head and neck cancer, the authors of a recent study found that surveillance imaging with PET/CT, MRI or CT did not improve outcomes in comparison to expectant management.
CT News: American Cancer Society Issues Updated Lung Cancer Screening Recommendations
November 2nd 2023In a newly updated guidance, the American Cancer Society recommends the expansion of annual lung cancer screening with low-dose computed tomography (LDCT) for current or previous smokers 50 to 80 years of age who have a 20-pack-year or greater history of smoking.
Annalise ai Introduces Radiology Triage Platform for Head CT and Chest X-Ray Exams
November 1st 2023Featuring 12 prior FDA clearances for chest X-ray and non-contrast head CT, the Annalise Triage platform may help streamline radiology workflows and prioritize timely diagnosis of urgent conditions.
